BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Ipilimumab

First Posted Date: 2014-10-31

Last Posted Date: 2019-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 82

Registration Number: NCT02279862

Locations: 🇮🇹
Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy
🇩🇪
Universitaetsklinikum Aachen, Aachen, Germany
🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 19 locations

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Phase 3

Completed

Conditions: Lung Cancer (NSCLC)

Interventions: Biological: Paclitaxel
Biological: Carboplatin
Biological: Ipilimumab
Other: Placebo

First Posted Date: 2014-10-31

Last Posted Date: 2019-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 342

Registration Number: NCT02279732

Locations: 🇭🇺
Csongrad Megyei Onkormanyzat Mellkasi Betegsegek Szakkorhaza, Deszk, Hungary
🇵🇱
Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland
🇵🇱
Oddzial Chemioterapii, Poznan, Poland

and more 4 locations

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

Phase 1

Completed

Conditions: Immune Thrombocytopenic Purpura

Interventions: Drug: BMS-986004 75 mg IV
Drug: BMS-986004 1500 mg IV
Drug: BMS-986004 225 mg IV
Drug: BMS-986004 675 mg IV

First Posted Date: 2014-10-24

Last Posted Date: 2019-07-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT02273960

Locations: 🇵🇱
Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych, Chorzow, Poland
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Rutgers- Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 7 locations

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Biological: Elotuzumab (BMS-901608)

First Posted Date: 2014-10-23

Last Posted Date: 2022-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 82

Registration Number: NCT02272803

Locations: 🇯🇵
Local Institution, Kasama-shi, Japan

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Lupus

Interventions: Drug: BMS-931699
Drug: Placebo matching BMS-931699

First Posted Date: 2014-10-16

Last Posted Date: 2019-10-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 730

Registration Number: NCT02265744

Locations: 🇺🇸
The Arthritis Center, Palm Harbor, Florida, United States
🇺🇸
Coeur D'Alene Arthrit Clin, Coeur d'Alene, Idaho, United States
🇺🇸
Heartland Research Associates, Llc, Wichita, Kansas, United States

and more 75 locations

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Phase 1

Completed

Conditions: N/A - Healthy Subjects

Interventions: Drug: Apixaban
Drug: Atenolol

First Posted Date: 2014-10-13

Last Posted Date: 2015-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT02262533

Locations: 🇺🇸
Bms Clinical Research Center, Hamilton, New Jersey, United States

Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: N/A - Healthy Subjects

Interventions: Drug: Apixaban
Drug: Digoxin

First Posted Date: 2014-10-13

Last Posted Date: 2015-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT02262520

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Adult

Interventions: Drug: BMS-986142
Drug: Placebo

First Posted Date: 2014-10-06

Last Posted Date: 2015-09-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT02257151

Locations: 🇺🇸
Wcct Global, Llc, Cypress, California, United States

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Advanced B-cell NHL
Advanced Solid Tumors

Interventions: Biological: Urelumab
Biological: Nivolumab

First Posted Date: 2014-10-01

Last Posted Date: 2020-10-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 232

Registration Number: NCT02253992

Locations: 🇺🇸
Stanford University School Of Medicine, Palo Alto, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
UPMC Cancer Center, Pittsburgh, Pennsylvania, United States

and more 11 locations

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Urelumab
Drug: Lirilumab

First Posted Date: 2014-09-30

Last Posted Date: 2017-11-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 44

Registration Number: NCT02252263

Locations: 🇪🇸
Local Institution, Pamplona, Navarra, Spain
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy